-
May 13, 2025
Allogeneic Engineered T Regulatory Cells Improve Disease Outcome in Preclinical Models of Acute Lung Injury
-
May 13, 2025
GNTI-932: A gut specific CAR-Engineered Regulatory T cell therapy to treat Inflammatory Bowel Disease
-
May 13, 2025
A Novel NK Inhibitor Provides “Best-in-Class Protection of HLA Knockout Allogeneic Human Engineered Regulatory T Cells to Effectively Evade Immune Rejection
-
May 13, 2025
A stable Engineered Regulatory T cell therapy platform with modular targeting for autoimmune and inflammatory disorders
-
May 13, 2025
Allogeneic Tissue Engineered Tregs for the Treatment of Ischemic Stroke and Neurodegenerative Diseases
-
April 17, 2025
CAR19 EngTregs offer broad capacity to modulate immune tolerance and improve safety in B and T cell mediated autoimmune disorders
-
June 16, 2024
A Tissue Engineered Treg Approach for the Treatment of Acute Ischemic and Inflammatory Diseases
-
May 31, 2024
Adoptive Transfer of Murine Engineered T Regulatory Cells Ameliorates Disease in a Model of Lipopolysaccharide Induced Acute Lung Injury
-
May 11, 2024
Stable Expression of FOXP3 and Core Tolerogenic Genes by Engineered Human Tregs
-
May 07, 2024
Characterization of Allogeneic Engineered Human Tissue-Tregs for Treatment of Acute Inflammatory Disease
-
April 23, 2024
Engineered Regulatory T cells ameliorate lung injury in the LPS model of acute lung injury
-
October 24, 2023
A novel engineered Treg platform that addresses Treg stability, IL-2 signaling and targeting, for the treatment of autoimmune diseases
-
June 20, 2023
Human Engineered Tregs maintain stability in inflammatory environment
-
May 23, 2023
Development of GNTI-122, a novel engineered regulatory T cell therapeutic, for future application in type 1 diabetes
-
October 11, 2022
Development and characterization of GNTI-122, an autologous engineered human regulatory T cell therapy for type 1 diabetes
-
June 05, 2022
Characterization and efficacy of engineered regulatory T-cell therapy, GNTI-122, for treating Type 1 Diabetes
-
May 16, 2022
GNTI-122 is a Dual-Engineered Regulatory T Cell Therapy Product for Type 1 Diabetes with Enhanced Stability, Tissue Specificity, and Tunable IL-2 Signaling
Toggle navigation